Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK8527-007)
Infectious Diseases
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8527 Once Monthly in Participants at Low Risk for HIV-1 Infection
The purpose of this study is to assess the safety and tolerance of MK-8527 administered once monthly at doses of 3 mg, 6 mg, and 12 mg throughout the treatment period and until the final follow-up visit. The study will specifically examine:
- Adverse events experienced by participants.
- Adverse events that result in the discontinuation of the study intervention.
Investigators
Dr Nicole Poovan (Primary Investigator)
Latest Update
April 2024
For more details about MK8527-007 please email rhicomms@wrhi.ac.za
Click here for further details regarding the MK8527-007 study.
